¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"stem cell factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • vascular permeability factor
    Ç÷°üÅõ°úÀÎÀÚ
  • virulence factor
    µ¶¼ºÀÎÀÚ, ¹ßº´ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • acantholytic cell
    °¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
  • angioimmunoblastic T-cell lymphoma
    Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ÀºÄ£È­¼¼Æ÷
  • argyrophilic cell
    ÀºÄ£È­¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • argentaffin cell
    ģũ·ÒÀº¼¼Æ÷
  • argyrophilic cell
    ÀºÄ£È­¼¼Æ÷
  • asexual cell
    ¹«¼º¼¼Æ÷
  • basal cell adenoma
    ±âÀú¼¼Æ÷»ùÁ¾, ¹Ù´Ú¼¼Æ÷¾ÏÁ¾
  • basosqumaous cell acanthoma
    ±âÀúÆíÆò¼¼Æ÷°¡½Ã¼¼Æ÷Á¾
  • cell-associated antibody
    ¼¼Æ÷ºÎÂøÇ×ü
  • cell-bound antibody
    (¢¡cell-fixed antibody) ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • B cell hybridoma
    B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • B cell lymphoma
    B¼¼Æ÷¸²ÇÁÁ¾
  • B cell study
    B ¼¼Æ÷°Ë»ç
  • B cell/lymphocyte
    B ¼¼Æ÷/¸²ÇÁ±¸
  • B-cell
    ºñ ¼¼Æ÷
  • C-cell
    C ¼¼Æ÷
  • CD4+ cell
    CD4+ ¼¼Æ÷
  • Cell adhesion molecules
    ¼¼Æ÷À¯ÂøºÐÀÚ
  • Chinese hamster ovary tumor cell
    Áß±¹ÇÔ½ºÅÍ ³­¼Ò¼¼Æ÷, CHO¼¼Æ÷
  • Graham cell
    ±×¶óÇÔ¼¼Æ÷
  • Granulosa cell
    °ú¸³¸·¼¼Æ÷(Î¨Ø£Ø¯á¬øà)
  • Granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç(Î¨Ø£Ø¯á¬øàðþåË)
  • H-9 cell line
    H-9 ¼¼Æ÷°è
  • HeLa cell
    Çï¶ó¼¼Æ÷.
  • HeLa cell
    Çï¶ó¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • dose conversion factor
    ¼±·®º¯È¯°è¼ö
  • dose limiting factor
    ¼±·®ÇѵµÀÎÀÚ, ¼±·®Á¦ÇÑÀÎÀÚ
  • dose modifying factor
    ¼±·®¼ö½Ä°è¼ö
  • dose-reduction factor
    ¼±·®°¨¼Ò°è¼ö
  • drug resistance factor
    ¾àÁ¦³»¼ºÀÎÀÚ
  • drug resistance transfer factor
    ¾àÁ¦³»¼ºÀü´ÞÀÎÀÚ
  • duplicate factor
    Áߺ¹ÀÎÀÚ.
  • early pregnancy factor(EPF)
    ÃʱâÀÓ½ÅÀÎÀÚ
  • edaphic factor
    ÅäÁöÀÎÀÚ(ÊÙËöËö).
  • elongation factor
    ¿¬ÀåÀÎÀÚ(¡­ì×í­).
  • elongation factor
    ½ÅÀåÀÎÀÚ
  • enabling factor
    ÀÇ·áÀÌ¿ë °¡´É¿äÀÎ.
  • encephalitogenic factor
    ³ú¿°À¯¹ßÀÎÀÚ
  • encephalitogenic factor
    ³ú¿°À¯¹ßÀÎÀÚ.
  • endothelium-derived contracting factor (EDCF)
    ³»ÇǼ¼Æ÷¼º¼öÃàÀÎÀÚ(Ò®ù«á¬øààõâ¥õêì×í­)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • Hair cell
    Åм¼Æ÷
    [¿¾ ¿ë¾î] À¯¸ð°¨°¢¼¼Æ÷
  • Juxtaglomerular cell
    Å丮°ç¼¼Æ÷
    [¿¾ ¿ë¾î] »ç±¸Ã¼¹æ¼¼Æ÷
  • Flagellated epithelial cell
    Æí¸ð»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Æí¸ð»óÇǼ¼Æ÷
  • Squamous epithelial cell
    ÆíÆò»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ÆíÆò»óÇǼ¼Æ÷
  • Squamous cell
    ÆíÆò¼¼Æ÷
    [¿¾ ¿ë¾î] ÆíÆò¼¼Æ÷
  • Phagocytic synovial cell
    Æ÷½ÄÀ±È°¼¼Æ÷
    [¿¾ ¿ë¾î] Ȱ¸·½Ä¼¼Æ÷
  • Superficial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ÀåÇ¥¸é¼¼Æ÷
  • Superficial epithelial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Ç¥¸é»óÇǼ¼Æ÷
  • Superficial epithelial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Ç¥Ãþ»óÇǼ¼Æ÷
  • Surface epithelial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Ç¥¸é»óÇǼ¼Æ÷
  • Superficial epithelial cell
    Ç¥¸é¼¼Æ÷
    [¿¾ ¿ë¾î] õ»óÇǼ¼Æ÷
  • Pyramidal cell
    ÇǶó¹Ô¼¼Æ÷
    [¿¾ ¿ë¾î] Ãßü¼¼Æ÷
  • Mesangial cell
    Ç÷°ü»çÀ̼¼Æ÷
    [¿¾ ¿ë¾î] Ç÷°ü°£¼¼Æ÷
  • Intravascular giant cell
    Ç÷°ü¼Ó°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] Ç÷°ü³»°Å´ë¿µ¾ç¸·¼¼Æ÷
  • Plasma cell
    ÇüÁú¼¼Æ÷
    [¿¾ ¿ë¾î] ÇüÁú¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
  • conversion factor
    ÀüȯÀÎÀÚ(ï®üµì×í­)
  • cord factor
    ÄÚµå ÀÎÀÚ(ì×í­)
  • coupling factor
    ¦Áþ±â ÀÎÀÚ(ì×í­)
  • decay factor
    "ºØ±« ÀÎÀÚ(ÝÚÎÕì×í­), (ÔÒ) decay constant"
  • diffusing factor
    "È®»êÀÎÀÚ(üªß¤ì×í­), (ÔÒ) hyaluronidase"
  • dissociation factor
    ÇØ¸®ÀÎÀÚ(ú°×îì×í­)
  • egg white injury factor
    ÈØÀÚ ¼Õ»óÀÎÀÚ (áßß¿ì×í­)
  • elongation factor
    ¿¬ÀåÀÎÀÚ (æÅíþì×í­)
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ (øúù«à÷íþì×í­)
  • epithelial growth factor
    »óÇǼºÀåÀÎÀÚ (ß¾ù«à÷íþì×í­)
  • erythrocyte maturation factor
    ÀûÇ÷±¸ ¼º¼÷ ÀÎÀÚ (îåúìϹà÷âÙì×í­)
  • extrinsic factor
    ¿ÜÀÎÀÚ(èâì×í­)
  • factor
    ÀÎÀÚ(ì×í­)
  • factor ¥°
    ÀÎÀÚ(ì×í­) I
  • factor ¥±
    ÀÎÀÚ(ì×í­) II
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
BSF back scatter factor; B-cell stimulatory factor; busulfan
MCF macrophage chemotactic factor; median cleft face; medium corpuscular fragility; microcomplement fixa...
TRF T-cell replacing factor; thyrotropin-releasing factor; tubular rejection fraction
FDC factor-dependent cell [line]; follicular dendritic cell
ADCC cell Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 11
PHSC Pluripotent hemopoietic stem cells
STEM Scanning Transmission Electron Microscope
S Stem
SLBP Stem-loop-binding protein
NCSCs neural crest stem cells
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • weighting factor
    °¡Áß°è¼ö
  • Abbe-Zeiss counting cell
    ¾Ðº£-ÀÚÀ̽º Ç÷±¸ °è»ê
  • abnormality of cell interaction
    ¼¼Æ÷ »óÈ£ÀÛ¿ë ÀÌ»ó
    ¼¼Æ÷ »çÀÌ¿¡ ÀϾ´Â ÀÛ¿ëÀÌ ºñÁ¤»óÀûÀÎ °Í.
  • absolute cell increase
    Àý´ë ¼¼Æ÷ ¼ö Áõ°¡
  • absorptive cell
    Èí¼ö ¼¼Æ÷
  • accessory cell
    ºÎ¼¼Æ÷
    °ñÀú¼± Áß¿¡¼­ ÁÖ¼¼Æ÷, ¹æ¼¼Æ÷¿¡ ¼¯¿©¼­ Á¸ÀçÇÑ´Ù. ÀÔ¹æÇüÀ̸ç Á¡¾×¼ºÀÇ ¹°ÁúÀ» °£Á÷ÇÑ´Ù. ÇÙÀº ¼¼Æ÷Àú¿¡ Ä¡¿ìÃÄ ÀÖ¾î ÆíÆò¿¡ °¡±õ´Ù.
  • acinic cell carcinoma
    ¼±¹æ ¼¼Æ÷ ¾ÏÁ¾
    1. ¼±¹æ ¼¼Æ÷, ±Ù»óÇǼ¼Æ÷°¡ Áõ½ÄÇÏ¿© Çü¼ºµÇ°í ³·Àº ¾Ç¼ºµµ¸¦ º¸ÀδÙ. 2. Ÿ¾×¼± ¾à¼º Á¾¾ç Áß 5¹øÂ°ÀÇ ¹ß»ý ºñÀ²À» °®´Â Á¾¾çÀ¸·Î 90%¿¡¼­ ÀÌÇϼ±¿¡¼­ ¹ß»ýÇÏ¸ç ¾ÇÇϼ±°ú ¼ÒŸ¾×¼±¿¡¼­µµ µå¹°°Ô ¹ß»ýÇÑ´Ù. ¿©¼º¿¡¼­ ´Ù¼Ò È£¹ßÇϰí, ¾î´À ¿¬·É¿¡¼­³ª ¹ß»ýÇϳª ÁÖ·Î 30-70´ë¿¡ °ñ°í·ç ¹ß»ýÇÑ´Ù. ¿¹Àü¿¡´Â ¾ç¼ºÀ¸·Î »ý°¢ÇÏ¿© ¼±¹æ¼¼Æ÷Á¾À̶ó ºÎ¸¥ ÀûÀÌ ÀÖÀ¸³ª ºÐ¸íÇÑ ¾Ç¼ºÀ¸·Î ¼±¾ÏÁ¾À¸·Î ºÎ¸¥´Ù. Á¾¾ç ¼¼Æ÷´Â Àå¾×¼º ¼±¹æ¼¼Æ÷¿Í À¯»çÇÏÁö¸¸ ¿©·¯ °¡Áö ´Ù¸¥ ¼¼Æ÷µéÀÌ ³ªÅ¸³ª¸ç, °³Á¦°ü ¿¹ºñ¼¼Æ÷¿¡¼­ ±â¿øÇÑ´Ù°í º»´Ù.
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç ±âÀú¼¼Æ÷¾Ï
  • adenoid basal cell carcinoma
    ¼±»ó ±âÀú¼¼Æ÷¾Ï
  • adenosquamous cell carcinoma
    ¼± ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ¼± ¾Ï°ú ÆíÆò¼¼Æ÷ ¾ÏÀÌ È¥ÀçµÇ¾î ÀÖ´Â °Í. ÀÚ±Ã°æ ³»¸· »óÇÇÀÇ ±âÀú Ãþ¿¡ ÀÖ´Â ¿¹ºñ ¼¼Æ÷¿¡¼­ ¹ß»ý. ÀÌ´Â °°Àº º´±âÀÇ ÆíÆò¼¼Æ÷ ¾Ï°ú ºñ±³ÇÏ¿© ¿¹Èİ¡ ´õ ³ª»Ú´Ù.
  • adipose cell
    Áö¹æ ¼¼Æ÷
    Áö¹æÀ» °¡Áø ¼¼Æ÷·Î¼­ ¼¼Æ÷´Â ±¸ÇüÀ» ÀÌ·ç°í, ÇÙÀº ÇÑ ÂÊÀ¸·Î Ä¡¿ìÃÄ ÀÖ´Ù.
  • adrenal medullary chromaffin cell
    ºÎ½Å ¼öÁú Å©·Ò ģȭ ¼¼Æ÷
  • adult T cell leukemia
    ¼ºÀÎ T¼¼Æ÷ ¹éÇ÷º´
    ¹ßÁõ ¿¬·ÉÀº Æò±Õ 51¼¼, ÀϺ» Kyushu, Shikoku, Kii ¹Ýµµ Áö¹æ¿¡¼­ ´Ù¹ßÇϰí ÇǺΠħÀ± ¹× °£Àå, ºñÀå, ¸²ÇÁÀý Á¾´ë¸¦ ÈçÈ÷ º¼ ¼ö Àִµ¥ ºóÇ÷Àº ¾ø´ø°¡, À־ °æµµ, °ñ¼ö¿¡ÀÇ Ä§À±Àº º¸Åë ÇöÀúÇÏÁö ¾Ê´Ù. 50% »ýÁ¸Àº 4.4°³¿ù·Î ª´Ù. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Æ¯Â¡Àº ÇÙÀÌ ÀÌÇüÀÌ¸ç ºÐ¿±»ó, È­ÆÇ»ó µîÀ¸·Î Áø´Ü¿¡ »ç¿ëµÈ´Ù.
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï
  • air cell
    ÇԱ⠼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 11
platelet factor 3 <haematology> Phospholipid associated with the platelet plasma membrane that contributes to the blood clotting cascade by forming a complex (thromboplastin) with other plasma proteins and activating prothrombin.
(31 Dec 1997)
platelet factor 4 <haematology> Platelet released protein that promotes blood clotting by neutralising heparin.
(31 Dec 1997)
platelet tissue factor <haematology> Traditional name for substance in plasma that converts prothrombin to thrombin. Now known not to be a single substance. (See thrombin).
(18 Nov 1997)
mullerian inhibiting factor A 535 amino acid glycoprotein secreted by the Sertoli cells of the testis. It is related to inhibin.
Synonym: mullerian inhibiting factor.
(05 Mar 2000)
mullerian regression factor Mullerian duct inhibitory factor, a non-steroidal substance of foetal testicular origin that acts unilaterally to inhibit development of the paramesonephric (mullerian) ducts and acts with testosterone to promote development of the vas deferens and related structures.
(05 Mar 2000)
multi-colony-stimulating factor <cytokine> Product of mitogen activated T-cells: colony-stimulating factor for bone marrow stem cells and mast cells.
A multilineage cell growth factor secreted by lymphocytes, epithelial cells, and astrocytes which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. It is considered one of the haematopoietic colony-stimulating factors.
Synonym: multi-CSF
Acronym: IL-3
(12 Dec 1998)
confounding factor <epidemiology> Factors that can cause or prevent the outcome of interest, are not intermediate variables, and are not associated with the factor(s) under investigation.
They give rise to situations in which the effects of two processes are not separated, or the contribution of causal factors cannot be separated, or the measure of the effect of exposure or risk is distorted because of its association with other factors influencing the outcome of the study.
(03 Jul 1999)
multipotential colony-stimulating factor <cytokine> Product of mitogen activated T-cells: colony-stimulating factor for bone marrow stem cells and mast cells.
A multilineage cell growth factor secreted by lymphocytes, epithelial cells, and astrocytes which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. It is considered one of the haematopoietic colony-stimulating factors.
Synonym: multi-CSF
Acronym: IL-3
(12 Dec 1998)
cord factor Glycolipid (trehalose 6, 6' dimycolate) found in the cell walls of Mycobacteria (causing them to grow in serpentine cords) and important in virulence, being toxic and inducing granulomatous reactions identical to those induced by the whole organism.
(18 Nov 1997)
corticotrophin releasing factor adrenocorticotrophin
corticotropin-releasing factor <endocrinology, physiology> A neuropeptide released by the hypothalamus that stimulates the release of corticotropin by the anterior pituitary gland.
Chemical name: Corticotropin-releasing factor
Synonym: corticoliberin, corticotropin releasing factor.
(12 Dec 1998)
myocardial depressant factor A low molecular weight peptide of about 800-1000 having a negative inotropic effect. It is released into the circulation during experimental haemorrhagic pancreatitis, severe ischemia, and postoligaemic shock.
(12 Dec 1998)
coupling factor Protein responsible for coupling transmembrane potentials to ATP synthesis in chloroplasts and mitochondria. Include ATP synthesising enzymes (F1 in mitochondrion), that can also act as ATP ases.
(18 Nov 1997)
Hageman factor <chemical> Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor xii to xiia. Deficiency of factor xii, also called the hageman trait, leads to increased incidence of thromboembolic disease.
Chemical name: Blood-coagulation factor XII
(12 Dec 1998)
Hageman factor assay A test used to measure the activity of a blood clotting factor XII. This test may be used to evaluate excessive bleeding. Low factor XII may be seen in cases of congenital deficiency of factor XII, heparin administration and liver disease.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 11
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 11
ÅëÇÕ°Ë»ö ¿Ï·á